Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07590102 | A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants | PHASE1 | NOT YET_RECRUITING | 30 | — | — | Jun 1, 2026 | Sep 30, 2026 | May 15, 2026 | - | — |
| Arm | Type | Description |
|---|---|---|
| Part A: BGB-58067 + Phenytoin (CYP3A Inducer) | EXPERIMENTAL | Participants will receive BGB-58067 on Day 1 and Day 18 and phenytoin on Days 4 to 20. |
| Part B: BGB-58067 + Itraconazole (CYP3A Inhibitor) | EXPERIMENTAL | Participants will receive BGB-58067 on Days 1 and 8 and itraconazole on Days 4 to 11. |
| Name | Type | Description |
|---|---|---|
| BGB-58067 | DRUG | Administered orally |
| Phenytoin | DRUG | Administered orally |
| Itraconazole | DRUG | Administered orally |
Inclusion Criteria: * Participants must sign the Informed Consent Form (ICF) and be capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol * Participants must be willing and able to comply with all study re...